Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC

ConclusionsThis study has identified a truncated dosing regimen and recommended phase II dose of demcizumab (5  mg/kg q3-weekly ×4) for subsequent clinical evaluation in combination with standard carboplatin and pemetrexed chemotherapy. NCT01189968.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research